Statements (63)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:pharmaceuticals
|
gptkbp:administered_by |
injection
|
gptkbp:approves |
gptkb:1991
gptkb:FDA |
gptkbp:available_on |
vial
pre-filled syringe |
gptkbp:class |
granulocyte colony-stimulating factor
|
gptkbp:clinical_trial |
Phase III
|
gptkbp:clinical_use |
preventing infection
enhancing recovery from bone marrow suppression supporting chemotherapy |
gptkbp:compatibility |
do not mix with other drugs
|
gptkbp:contraindication |
gptkb:sickle_cell_disease
hypersensitivity to filgrastim |
gptkbp:dosage_form |
gptkb:Software_Solutions
|
gptkbp:formulation |
sterile solution
|
https://www.w3.org/2000/01/rdf-schema#label |
Neupogen
|
gptkbp:indication |
bone marrow transplant
chemotherapy-induced neutropenia HIV/ AIDS-related neutropenia |
gptkbp:ingredients |
filgrastim
|
gptkbp:invention |
patented
|
gptkbp:is_a_guide_for |
ASCO guidelines
NCCN guidelines ECOG guidelines |
gptkbp:is_monitored_by |
complete blood count
|
gptkbp:manufacturer |
gptkb:Amgen
|
gptkbp:marketed_as |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
gptkbp:mechanism_of_action |
stimulates bone marrow
|
gptkbp:patient_population |
cancer patients
patients undergoing chemotherapy patients with bone marrow disorders |
gptkbp:pharmacokinetics |
subcutaneous absorption
reduces infection risk clearance via kidneys half-life of 3.5 hours increases neutrophil count |
gptkbp:price |
varies by region
|
gptkbp:related_to |
gptkb:pegfilgrastim
G-CSF |
gptkbp:research_areas |
hematology
cancer supportive care neutropenia treatment |
gptkbp:route_of_administration |
intravenous
subcutaneous |
gptkbp:shelf_life |
24 months
|
gptkbp:side_effect |
fatigue
headache nausea fever acute respiratory distress syndrome bone pain thrombocytopenia leukocytosis splenic rupture |
gptkbp:storage |
refrigerated
|
gptkbp:trade |
gptkb:Neupogen
|
gptkbp:used_for |
treating neutropenia
|
gptkbp:bfsParent |
gptkb:Immunex_Corporation
gptkb:Neulasta |
gptkbp:bfsLayer |
5
|